EU/3/16/1732

About

On 29 August 2016, orphan designation (EU/3/16/1732) was granted by the European Commission to Biogen Idec Limited, United Kingdom, for synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid (also known as BIIB067) for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of decision
29/08/2016
Outcome
Positive
Orphan decision number
EU/3/16/1732

Review of designation


The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Biogen Idec Limited
Innovation House
70 Norden Road
Maidenhead
Berkshire SL6 4AY
United Kingdom
Tel. +44 (0)1628 501 000
Fax +44 (0)1628 501 010
E-mail: ukreception@biogenidec.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating